Exenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes

Basit Öğe Kaydı
dc.contributor.authorCelikyurt, Ipek Komsuoglu
dc.contributor.authorMutlu, Oguz
dc.contributor.authorUlak, Guner
dc.contributor.authorUyar, Emre
dc.contributor.authorBektas, Emine
dc.contributor.authorAkar, Furuzan Yildiz
dc.contributor.authorErden, Faruk
dc.date.accessioned2024-04-24T17:15:09Z
dc.date.available2024-04-24T17:15:09Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model. Material/Methods: Modified elevated plus-maze test for anxiolytic- like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin - (100 mg/kg, i.p.) and nicotinamide - (240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 mu g/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested. Results: Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model. Conclusions: Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.en_US
dc.description.sponsorshipNovo Nordisk drug companyen_US
dc.description.sponsorshipNovo Nordisk drug companyen_US
dc.identifier.doi10.12659/MSMBR.891168
dc.identifier.endpage117en_US
dc.identifier.issn2325-4416
dc.identifier.issn2325-4394
dc.identifier.pmid25076419
dc.identifier.startpage112en_US
dc.identifier.urihttps://doi.org/10.12659/MSMBR.891168
dc.identifier.urihttps://hdl.handle.net/11468/18353
dc.identifier.volume20en_US
dc.identifier.wosWOS:000218477300016
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInt Scientific Information, Incen_US
dc.relation.ispartofMedical Science Monitor Basic Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Anxiety Agentsen_US
dc.subjectBehavioren_US
dc.subjectAnimalen_US
dc.subjectDepressionen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectType 2en_US
dc.subjectGlucagon-Like Peptide 1en_US
dc.titleExenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetesen_US
dc.titleExenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu